TARS

Tarsus Pharmaceuticals, Inc. [TARS] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TARS Stock Summary

Top TARS Correlated Resources

TARS

Top 10 Correlated ETFs

TARS

Top 10 Correlated Stocks

TARS

In the News

TARS Financial details

Company Rating
-
Market Cap
1.36B
Income
-134.36M
Revenue
32.72M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
244
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-5.94
Forward P/E
-
PEG
-0.73
P/S
22.87
P/B
2.94
P/C
-
P/FCF
-7.16
Quick Ratio
10.89
Current Ratio
11.15
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-4.58
EPS next Y
-
EPS next Q
-
EPS this Y
83.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
598.88%
EPS Q/Q
2.34%
-
-
-
-
SMA20
7.22%
SMA50
-0.77%
SMA100
53.09%
Inst Own
-
Inst Trans
-
ROA
-39%
ROE
-58%
ROC
-0.46%
Gross Margin
97%
Oper. Margin
-384%
Profit Margin
-356%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
11.33-40.4
52W High
+19.6%
52W Low
+334.91%
RSI
39.21
Rel Volume
0.59
Avg Volume
791.99K
Volume
465.33K
Perf Week
-6.6%
Perf Month
-13.14%
Perf Quarter
79.98%
Perf Half Y
83.44%
-
-
-
-
Beta
1.054
-
-
Volatility
1.57%, 3%
Prev Close
-1.81%
Price
47.84
Change
-3.12%

Something similar

Top by Market Cap
LLY
0YXG.L
NVDA
MSF.DE
3V64.DE
Top Correlated ETFs
WCLD
RTH
IYH
FHLC
RXL
Top Correlated Stocks
0I04.L
LNSR
HBCP
RMBI
HSIC
Similar Market Cap
RADI
TRIG.L
ITCB
KIE
AIR.NZ

Company Profile

Healthcare Biotechnology
  • Volume Average 791.99K
  • Market Capitalization 1.36B
  • Employee 244
  • CEO Dr. Bobak R. Azamian M.D.
  • Headquarters Irvine,CA,US
  • IPO Date 2020-10-16
  • Website https://www.tarsusrx.com

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.